Tag: 300-400

On October 7, 2010, Neelamkavil, Santhosh Francis; Neustadt, Bernard R.; Stamford, Andrew; Xia, Yan; Harris, Joel M.; Boyle, Craig D.; Chackalamannil, Samuel; Biswas, Dipshikha; Liu, Hong; Hao, Jinsong; Lankin, Claire M.; Shah, Unmesh G. published a patent.Electric Literature of 227940-70-7 The title of the patent was Bridged bicyclic heterocycle derivatives as GPCR modulators and their preparation and use in the treatment of GPCR-related disorders. And the patent contained the following:

The invention relates to bridged bicyclic heterocycle derivatives of formula I, compositions comprising compounds of formula I, and methods of using compounds of formula I for treating or preventing disorders related to the activity of a GPCR in a patient. Compounds of formula I wherein A is (un)substituted pyridyl and pyrimidinyl; B is (un)substituted Ph and (un)substituted heteroaryl; W is a bond, CO, CONH, CO2, COS, and SO2; X is O, oxyalkylene and NH; Y is O and NH; Z is a bond, CO, (un)substituted methylene, O, SO2, and NH and derivatives; R3 is alkyl, alkylenearyl, cycloalkyl, alkylenecycloalkyl, etc.; D, E, F, Q, and U are independently absent and CH2; and their pharmaceutically acceptable salts, solvates, esters, prodrugs and stereoisomers, are claimed. Example compound II was prepared by a multistep procedure (procedure given). All the invention compounds were evaluated for their GPCR modulatory activity. From the assay, it was determined that the invention compounds exhibited EC50 values in the range from about 3 nM to about 200 nM. The experimental process involved the reaction of tert-Butyl 7-benzyl-9-oxo-3,7-diazabicyclo[3.3.1]nonane-3-carboxylate(cas: 227940-70-7).Electric Literature of 227940-70-7

The Article related to bridge bicyclic heterocycle derivative preparation gpcr modulator treatment disorder, Heterocyclic Compounds (More Than One Hetero Atom): Eight- and Higher-Membered Rings and other aspects.Electric Literature of 227940-70-7

Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

On June 6, 2012, Han, Haitao; Pan, Jianfeng; Jiang, Zhigan; Hu, Tao; Ma, Rujian; Chen, Shuhui published a patent.Application In Synthesis of tert-Butyl 7-benzyl-9-oxo-3,7-diazabicyclo[3.3.1]nonane-3-carboxylate The title of the patent was A process for preparing diazabicyclo[3.3.1]nonane derivatives. And the patent contained the following:

The invention relates to a process for the preparation of diazabicyclo[3.3.1]nonane derivative I, useful as intermediate for manufacturing antiarrhythmic drugs. For instance, the compound I was prepared by heterocyclization of N-Boc-4-oxopiperidine with formaldehyde and benzylamine followed by addition to 1-[(isocyanomethyl)sulfonyl]-4-methyl-benzene, hydrolysis, protection with (Boc)2O, reduction, and protection with CbzCl. The experimental process involved the reaction of tert-Butyl 7-benzyl-9-oxo-3,7-diazabicyclo[3.3.1]nonane-3-carboxylate(cas: 227940-70-7).Application In Synthesis of tert-Butyl 7-benzyl-9-oxo-3,7-diazabicyclo[3.3.1]nonane-3-carboxylate

The Article related to diazabicyclononane derivative preparation antiarrhythmic intermediate, Heterocyclic Compounds (More Than One Hetero Atom): Eight- and Higher-Membered Rings and other aspects.Application In Synthesis of tert-Butyl 7-benzyl-9-oxo-3,7-diazabicyclo[3.3.1]nonane-3-carboxylate

Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

On April 11, 2013, Boss, Christoph; Brotschi, Christine; Heidmann, Bibia; Sifferlen, Thierry; Williams, Jodi T. published a patent.Reference of tert-Butyl 7-benzyl-9-oxo-3,7-diazabicyclo[3.3.1]nonane-3-carboxylate The title of the patent was Preparation of diazabicyclononane derivatives for use as orexin receptor antagonists. And the patent contained the following:

Title compounds I [A = (un)substituted Ph or heteroaryl; B = (un)substituted heteroaryl; X = CH2 or O], and their pharmaceutically acceptable salts, are prepared and disclosed as orexin receptor antagonists. Thus, e.g., II was prepared by a multistep procedure (preparation given). I were evaluated in OX1 receptor assays, e.g., II demonstrated an IC50 value of 8 nM. The experimental process involved the reaction of tert-Butyl 7-benzyl-9-oxo-3,7-diazabicyclo[3.3.1]nonane-3-carboxylate(cas: 227940-70-7).Reference of tert-Butyl 7-benzyl-9-oxo-3,7-diazabicyclo[3.3.1]nonane-3-carboxylate

The Article related to diazabicyclononane derivative preparation orexin receptor antagonist, Heterocyclic Compounds (More Than One Hetero Atom): Eight- and Higher-Membered Rings and other aspects.Reference of tert-Butyl 7-benzyl-9-oxo-3,7-diazabicyclo[3.3.1]nonane-3-carboxylate

Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

On May 2, 2006, Baldwin, John J.; Tran, Vinh D. published a patent.HPLC of Formula: 227940-70-7 The title of the patent was Preparation of a diazabicyclononane scaffold which is useful in for combinatorial synthesis. And the patent contained the following:

Diazabicyclononanes [I; A = CHNHR1; R1 = H, residue of a solid substrate; R2 = H, amino-protecting group; with the proviso that no more than one of R1, R2 and R3 is H; e.g., II] and their synthesis are described and are useful as scaffolds for constructing combinatorial libraries. The experimental process involved the reaction of tert-Butyl 7-benzyl-9-oxo-3,7-diazabicyclo[3.3.1]nonane-3-carboxylate(cas: 227940-70-7).HPLC of Formula: 227940-70-7

The Article related to diazabicyclononane preparation scaffold combinatorial synthesis, Heterocyclic Compounds (More Than One Hetero Atom): Eight- and Higher-Membered Rings and other aspects.HPLC of Formula: 227940-70-7

Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

On June 24, 1999, Strandlund, Gert; Alstermark, Christer; Bjore, Annika; Bjorsne, Magnus; Frantsi, Marianne; Halvarsson, Torbjorn; Hoffmann, Kurt-Jurgen; Lindstedt, Eva-Lotte; Polla, Magnus published a patent.HPLC of Formula: 227940-70-7 The title of the patent was Preparation of 3,7-diazabicyclo[3.3.1]nonane-3-carboxylates as antiarrhythmic agents. And the patent contained the following:

Title compounds [I; R1,R2 = H or alkyl; R1R2 = OCH2CH2O, (CH2)4-5; R3 = CCR10R11AR; A = bond, alkylene, (CH2)nZ, CONR20, etc.; B = bond, alkylene, NR23(CH2)r, O(CH2)r; R = (un)substituted Ph; R4 = COXR9; R9 = alkyl, (un)substituted phenyl(alkyl), -naphthyl; R10 = H or OH; R11,R20,R23 = H or alkyl; X = O or S; Z = NR20, SO0-2, O; n,r = 0-4] were prepared Thus, 4-(NC)C6H4OH was condensed with epichlorohydrin and the product aminated by I (R1 = R2 = H, R4 = CO2CMe3)(II; R3 = H)(preparation given) to give II [R3 = CH2CH(OH)CH2OC6H4(CN)-4]. Data for biol. activity of I were given. The experimental process involved the reaction of tert-Butyl 7-benzyl-9-oxo-3,7-diazabicyclo[3.3.1]nonane-3-carboxylate(cas: 227940-70-7).HPLC of Formula: 227940-70-7

The Article related to diazabicyclononanecarboxylate preparation antiarrhythmic agent, Heterocyclic Compounds (More Than One Hetero Atom): Eight- and Higher-Membered Rings and other aspects.HPLC of Formula: 227940-70-7

Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

On October 31, 2015, Stead, Darren; O’Brien, Peter; Sanderson, Adam published an article.Name: tert-Butyl 7-benzyl-9-oxo-3,7-diazabicyclo[3.3.1]nonane-3-carboxylate The title of the article was Investigation of the Lithiation-Trapping of an N-BOC Bispidine-Ketal: Reactivity and Diastereoselectivity. And the article contained the following:

The lithiation-trapping of an N-BOC bispidine-ketal using BuLi/TMEDA has been studied. Key findings include an activating effect of the 4-ketal group on the lithiation and complete diastereoselectivity with methylation and Cu-mediated allylation. In contrast, reduced diastereoselectivity was noted for direct allylation and silylation; mechanistic explanations are proposed. The synthesis of the target compounds was achieved using 7-(phenylmethyl)-3,7-diazabicyclo[3.3.1]nonane-3-carboxylic acid 1,1-dimethylethyl ester (i.e., a bispidine carboxylic acid ester derivative), 9-oxo-7-(phenylmethyl)-3,7-diazabicyclo[3.3.1]nonane-3-carboxylic acid 1,1-dimethylethyl ester (i.e., a bispidine-ketone derivative), 7-(phenylmethyl)Spiro[3,7-diazabicyclo[3.3.1]nonane-9,2′-[1,3]dioxolane]-3-carboxylic acid 1,1-dimethylethyl ester (i.e., a cyclic-ketal-bispidine derivative) as starting materials. The title compounds thus formed included bispidine-diastereomer derivatives, such as (1R,2S,5S)-rel-7-(phenylmethyl)-2-(2-propen-1-yl)-3,7-diazabicyclo[3.3.1]nonane-3-carboxylic acid 1,1-dimethylethyl ester. The experimental process involved the reaction of tert-Butyl 7-benzyl-9-oxo-3,7-diazabicyclo[3.3.1]nonane-3-carboxylate(cas: 227940-70-7).Name: tert-Butyl 7-benzyl-9-oxo-3,7-diazabicyclo[3.3.1]nonane-3-carboxylate

The Article related to lithiation bispidine ketal diastereoselectivity, Heterocyclic Compounds (More Than One Hetero Atom): Eight- and Higher-Membered Rings and other aspects.Name: tert-Butyl 7-benzyl-9-oxo-3,7-diazabicyclo[3.3.1]nonane-3-carboxylate

Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

On September 30, 2022, Petrovics, Noemi; Kirchkeszner, Csaba; Tabi, Tamas; Magyar, Norbert; Kovacsne Szekely, Ilona; Szabo, Balint Samuel; Nyiri, Zoltan; Eke, Zsuzsanna published an article.Name: 2-Ethylhexyl 2-cyano-3,3-diphenylacrylate The title of the article was Effect of temperature and plasticizer content of polypropylene and polylactic acid on migration kinetics into isooctane and 95 v/v% ethanol as alternative fatty food simulants. And the article contained the following:

Plasticizers are commonly used plastic additives. Deep understanding of their effect on the migration of other substances is essential, especially for food contact materials. The migration kinetics of four stabilizer-type additives from polypropylene (PP) and polylactic acid (PLA) with different tri-Bu acetyl citrate plasticizer content were investigated. The results confirm that the presence of plasticizer in the plastics enhances swelling, and thus the migration of additives. The plasticizer content is in strong correlation with migration rate for all additives, except for PLA-Irgafos 168 samples. Migration kinetic experiments conducted at different contact temperatures showed that the role of temperature apparently exceeds that of plasticization. Nevertheless, hierarchical cluster anal. revealed similarity in the migration mechanisms of stabilizers from plastics with low plasticizer content at high temperature, to that at low temperature from plastics with high plasticizer content. The experimental process involved the reaction of 2-Ethylhexyl 2-cyano-3,3-diphenylacrylate(cas: 6197-30-4).Name: 2-Ethylhexyl 2-cyano-3,3-diphenylacrylate

The Article related to polypropylene polylactic acid isooctane ethanol migration fatty food simulant, Food and Feed Chemistry: Additives, Sweeteners, Flavorings, Condiments, and Confectionery and other aspects.Name: 2-Ethylhexyl 2-cyano-3,3-diphenylacrylate

Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

On June 21, 2021, Geng, Jun-shan; Liu, Kang; Liang, Yuan-yuan; Yu, Ji-pan; Hu, Kong-qiu; Yuan, Li-Hua; Feng, Wen; Chai, Zhi-fang; Mei, Lei; Shi, Wei-qun published an article.SDS of cas: 1312703-30-2 The title of the article was An Azobenzene-Modified Photoresponsive Thorium-Organic Framework: Monitoring and Quantitative Analysis of Reversible trans-cis Photoisomerization. And the article contained the following:

Monitoring and quantification of the photoresponsive behavior of metal-organic frameworks that respond to a light stimulus are crucial to establish a clear structure-activity relationship related to light regulation. Herein, we report the first azobenzene-modified photoresponsive thorium-organic framework (Th-Azo-MOF) with the formula [Th6O4(OH)4(H2O)6L6] (H2L = (E)-2′-p-tolyldiazenyl-1,1′:4′,4′-terphenyl-4,4”-dicarboxylic acid), in which the utilization of a thorium cluster as a metal node leads to one of the largest pore sizes among all the azobenzene-containing metal-organic frameworks (MOFs). The phototriggered transformation of the trans isomer to the cis isomer is monitored and characterized quant. by comprehensive analyses of NMR and UV spectroscopy, which reveals that the maximum isomerization ratio of cisTh-Azo-MOF in the solid state is 19.7% after irradiation for 120 min, and this isomerization is reversible and can be repeated several times without apparent performance changes. Moreover, the isomerization-related difference in the adsorption of the Rhodamine B guest is also illustrated and a possible photoregulated mechanism is proposed. This work will shed light on new explorations for constructing functionalized actinide porous materials by the elegant combination of actinide nodes with tailored organic ligands and furthermore will provide a comprehensive understanding of photoisomerization processes in MOF solids and insight into the mechanism on photoregulated cargo adsorption and release by photoactive MOFs. The experimental process involved the reaction of Dimethyl 2′-amino-[1,1′:4′,1”-terphenyl]-4,4”-dicarboxylate(cas: 1312703-30-2).SDS of cas: 1312703-30-2

The Article related to azobenzene modified photoresponsive thorium organic framework crystallog, reversible trans cis photoisomerization mof thorium, Physical Organic Chemistry: Rearrangements, Including Isomerization and Tautomerization and other aspects.SDS of cas: 1312703-30-2

Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

On February 6, 2020, Crew, Andrew P.; Wang, Jing; Berlin, Michael; Dragovich, Peter; Chen, Huifen; Staben, Leanna published a patent.Application of 882518-89-0 The title of the patent was Preparation of pyridazinamine derivatives as modulators of SMARCA2 and BRM target proteins and associated methods of use. And the patent contained the following:

The disclosure relates to bifunctional compounds of formula I, which find utility as modulators of SMARCA2 or BRM (target protein). The disclosure is directed to bifunctional compounds of formula I, which contain on one end a ligand that binds to the Von Hippel-Lindau E3 ubiquitin ligase, and on the other end a moiety which binds the target protein, such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of target protein. Compounds of formula I wherein ULM is a small mol. E3 ubiquitin ligase binding moiety that binds a Von Hippel-Lindau E3 ubiquitin ligase; L is a bond and a chem. linker; PTM is a small mol. comprising a SMARCA2 protein targeting moiety; and pharmaceutically acceptable salts, enantiomers, stereoisomers, solvates, polymorphs and prodrugs thereof, are claimed. The disclosure exhibits a broad range of pharmacol. activities associated with degradation/inhibition of target protein. Diseases or disorders that result from aggregation or accumulation of the target protein are treated or prevented with compounds and compositions of the disclosure. Example compound II was prepared by a multistep procedure (procedure given). The invention compounds were evaluated for their SMARCA2 and BRM modulatory activity. From the assay, it was determined that compound II exhibited DC50 value of ≥ 30 nM and Dmax value of > 75%. The experimental process involved the reaction of tert-Butyl 2-(2-(2-(tosyloxy)ethoxy)ethoxy)acetate(cas: 882518-89-0).Application of 882518-89-0

The Article related to pyridazine preparation smarca2 brm protein modulator, Heterocyclic Compounds (More Than One Hetero Atom): Pyridazines, Cinnolines, and Phthalazines and other aspects.Application of 882518-89-0

Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

On April 8, 2021, Crew, Andrew P.; Wang, Jing; Berlin, Michael; Dragovich, Peter; Chen, Huifen; Staben, Leanna published a patent.Synthetic Route of 882518-89-0 The title of the patent was Preparation of pyridazinamine derivatives as modulators of SMARCA2 and BRM target proteins and associated methods of use. And the patent contained the following:

The disclosure relates to bifunctional compounds of formula I, which find utility as modulators of SMARCA2 or BRM (target protein). The disclosure is directed to bifunctional compounds of formula I, which contain on one end a ligand that binds to the Von Hippel-Lindau E3 ubiquitin ligase, and on the other end a moiety which binds the target protein, such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of target protein. Compounds of formula I wherein ULM is a small mol. E3 ubiquitin ligase binding moiety that binds a Von Hippel-Lindau E3 ubiquitin ligase; L is a bond and a chem. linker; PTM is a small mol. comprising a SMARCA2 protein targeting moiety; and pharmaceutically acceptable salts, enantiomers, stereoisomers, solvates, polymorphs and prodrugs thereof, are claimed. The disclosure exhibits a broad range of pharmacol. activities associated with degradation/inhibition of target protein. Diseases or disorders that result from aggregation or accumulation of the target protein are treated or prevented with compounds and compositions of the disclosure. Example compound II was prepared by a multistep procedure (procedure given). The invention compounds were evaluated for their SMARCA2 and BRM modulatory activity. From the assay, it was determined that compound II exhibited DC50 value of ≥ 30 nM and Dmax value of > 75%. The experimental process involved the reaction of tert-Butyl 2-(2-(2-(tosyloxy)ethoxy)ethoxy)acetate(cas: 882518-89-0).Synthetic Route of 882518-89-0

The Article related to pyridazine preparation smarca2 brm protein modulator, Heterocyclic Compounds (More Than One Hetero Atom): Pyridazines, Cinnolines, and Phthalazines and other aspects.Synthetic Route of 882518-89-0

Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics